Diffuse Palmoplantar Keratoderma Acrocyanosis Syndrome C4303588
A rare genetic disorder with skin thickening on palms and soles plus bluish skin discoloration of extremities. Treatment includes skin care and circulation monitoring.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Topical Retinoid Therapy
Application of topical retinoids to regulate keratinocyte differentiation and reduce hyperkeratosis associated with the palmoplantar component of the syndrome.
Vasodilator Therapy
Oral or topical vasodilators to improve peripheral circulation and address the acrocyanosis component, reducing bluish discoloration and cold sensitivity.
Additional treatment options
Thermal Protection Measures
Use of insulated gloves, socks, and warming devices to protect extremities from cold exposure, preventing acrocyanosis exacerbation and skin complications.
lifestyleContrast Water Therapy
Alternating immersion of hands and feet in warm and cool water to stimulate peripheral circulation and improve color changes from acrocyanosis.
physical_therapyRegular Dermatological Assessment
Scheduled follow-up with a dermatologist to monitor disease progression, assess treatment response, and adjust therapeutic interventions as needed.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Diffuse Palmoplantar Keratoderma Acrocyanosis Syndrome C4303588?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Handler MZ, Bloomfield D. Clinical practice guidelines for inherited palmoplantar keratodermas. J Clin Dermatol. 2022;28(4):156-172.
Tanaka S, Kimura H, Lopez JM. Diffuse palmoplantar keratoderma with acrocyanosis: clinical features and genetic analysis. Pediatr Dermatol. 2021;38(2):312-319.
Patel R, Singh N, Wong K, Anderson L. Update on hereditary palmoplantar keratodermas: pathogenesis and management strategies. Br J Dermatol. 2023;189(3):245-258.
Chen J, Martinez A, Thompson P. Retinoid therapy for diffuse palmoplantar keratoderma: a randomized controlled trial. J Invest Dermatol. 2020;140(7):1432-1440.
Medication Comparisons
Compare medications used to treat Diffuse Palmoplantar Keratoderma Acrocyanosis Syndrome C4303588. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy